Understanding and managing secondary osteoporosis.

Area of Science:

• Endocrinology
• Metabolic Bone Disease
• Rheumatology

Background:

• Secondary osteoporosis (SO) is defined as bone mass reduction due to underlying diseases or medications.
• Identifying the cause of SO presents a significant clinical challenge.
• Prevalence of SO varies widely, emphasizing the need for its investigation in osteoporosis patients.

Purpose of the Study:

• To review recent advancements in the understanding and management of secondary osteoporosis.
• To emphasize the importance of recognizing SO in clinical practice, especially when the cause is unclear or treatment is ineffective.
• To highlight the current gaps in treatment guidelines for most forms of SO.

Main Methods:

• Literature review of recent advances in secondary osteoporosis.
• Analysis of prevalence data and clinical challenges in SO identification.
• Discussion of current treatment guidelines and research gaps.

Main Results:

• SO is a common condition, with prevalence ranging from 17% to 80%.
• Specific guidelines exist for some forms (e.g., glucocorticoid-induced osteoporosis) but are often overlooked.
• Few trials have assessed the efficacy of bone-active drugs in reducing fracture risk for most SO types.
• Bone biopsy may be necessary in specific complex cases.

Conclusions:

• Healthcare professionals must maintain awareness of SO, particularly in cases of uncertain etiology or poor treatment response.
• Further research and specific guidelines are needed for the effective management of the majority of SO cases.
• Advances in understanding SO are crucial for improving patient outcomes and skeletal health.